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PQUARTERLY FOCUS ISSUE: HEART RHYTHM DISORDERS
A Comparison of Atrial Arrhythmias After Heart or
Double-Lung Transplantation at a Single Center
Insights Into the Mechanism of Post-Operative Atrial Fibrillation
José Dizon, MD,* Kimberly Chen,* Matthew Bacchetta, MD,† Michael Argenziano, MD,†
Donna Mancini, MD,* Angelo Biviano, MD,* Joshua Sonett, MD,† Hasan Garan, MD*
New York, New York
Objectives We compared the incidence of atrial arrhythmias in double-lung transplant patients versus heart transplant pa-
tients to gain insight into factors that contribute to post-operative atrial fibrillation (AF).
Background Atrial fibrillation is a common complication after thoracic surgery. Pulmonary vein isolation is an effective treatment
for AF. Heart or double-lung transplantation surgery both involve pulmonary vein isolation because of suture lines.
Methods We reviewed the records of 174 consecutive heart transplant patients and 122 double-lung transplant patients
at the Columbia Presbyterian Medical Center between January 2005 and June 2008. Electrocardiograms during
atrial arrhythmia episodes were reviewed by an electrophysiologist. Clinical variables, biopsy results, immuno-
suppressive regimens, and echocardiographic measurements were collected from the perioperative time period
and at the time of arrhythmia occurrence.
Results In the heart transplant group, 8 (4.6%) patients had AF (group A). In the lung transplant group, 23 (18.9%) pa-
tients had AF (group B; p  0.001). The incidence of AF in a comparison group of 131 patients with normal left
ventricular function who underwent coronary artery bypass graft surgery was 19.8%. Immunosuppressive regi-
mens and clinical variables were similar for both groups. Echocardiographic data revealed no significant cardiac
abnormalities in 74% of group B compared with 25% of group A (p  0.05), and 78% of biopsy results in group
B were normal, whereas only 25% of group A results were normal (p  0.05).
Conclusions In heart transplant recipients, AF is uncommon and occurs in the setting of myocardial dysfunction and graft
rejection. In contrast, AF is more common after lung transplantation despite the absence of graft rejection and
cardiac dysfunction. Pulmonary vein isolation alone cannot explain the discrepancy in AF incidence between
heart transplant recipients and double-lung transplant recipients. Cardiac autonomic denervation may have a
protective effect for heart transplant patients in the post-operative setting. (J Am Coll Cardiol 2009;54:
2043–8) © 2009 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.08.029s
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wtrial fibrillation (AF) is a common complication after
horacic surgery, with an incidence approaching 50% in
ome series (1,2). Multiple mechanisms may underlie post-
perative AF, and various studies have aimed at predicting
ts occurrence (3–5). Recently, pulmonary vein isolation
PVI) using catheter and surgical approaches has been
hown to be effective in treating paroxysmal or persistent
F (6–8). The efficacy of these techniques approaches 90%
n some series (9–12).
The most common techniques in heart or double-lung
ransplantation effectively cause PVI due to suture lines.
he incidence of post-operative AF in heart transplant
rom the Departments of *Medicine and †Surgery, Columbia Presbyterian Medical
enter, New York, New York. Dr. Argenziano serves as a consultant for ESTECH, Inc.n
Manuscript received June 4, 2009; revised manuscript received August 19, 2009,
ccepted August 24, 2009.eries is known to be low (13–16), whereas the same
ncidence in post–lung transplant patients appears to be
igher (17,18). It is not known whether differences in pre-
r post-transplant clinical variables, cardiac function, surgi-
al technique, immunosuppressive regimens, or allograft
ejection explain the difference in AF rates after heart
ransplantation compared to lung transplantation.
See page 2049
The purpose of this study is to analyze the incidence of
F after heart or double-lung transplantation in a single
nstitution with a large volume of both procedures.
linical variables, echocardiographic measurements, im-
unosuppressive regimens, and biopsy results of patients
ith AF were compared to gain insight into the mecha-
isms of post-operative AF. Because atrial flutter (AFL)
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Atrial Arrhythmias After Heart or Double-Lung Transplantation November 24, 2009:2043–8is often associated with AF and
also occurs commonly after
thoracic surgery, we recorded
episodes of AFL as well.
Methods
The records of 174 consecutive
adult heart transplant and 122
double-lung transplant patients at
the Columbia Presbyterian Medi-
cal Center from January 2005 to
une 2008 were reviewed. The review included inpatient and
utpatient charts, discharge summaries, operative reports, and
ll other available records in paper or electronic form. Any
otation of an atrial arrhythmia such as AF or AFL was
nvestigated, and the corresponding electrocardiogram (ECG)
as located and copied. If the ECG corresponding to a noted
rrhythmia episode could not be located, that episode was not
ncluded in the analysis. An arrhythmia episode is defined as
he occurrence of AF or AFL lasting 30 min. If episodes
ere separated by 24 h, they were counted as individual
pisodes.
The ECGs were reviewed in a blinded fashion by a
oard-certified electrophysiologist and classified as AFL,
F, or neither. When the ECG reading was uncertain, a
econd electrophysiologist was asked to read the ECG and
consensus reading was determined. Perioperative and
ost-operative data from the group of transplant patients
ith confirmed AF or AFL were then collected. These
ncluded clinical variables, echocardiographic data, immuno-
uppressive regimens, and biopsy results. Clinical data at the
ime of arrhythmia occurrence were particularly scrutinized.
As a control, data from a contemporary group of 131
atients with preserved left ventricular function who had
ndergone coronary artery bypass graft surgery (CABG),
nd who also did not have a pre-operative history of AF or
Figure 1 Double-Lung Transplant Procedure
Schematic of double-lung transplantation procedure depicting separate recipi-
ent left atriotomies for anastomoses of donor left and right pulmonary veins
(PVs). Donor lung pulmonary arteries (PAs) are anastomosed to recipient PAs.
Abbreviations
and Acronyms
AF  atrial fibrillation
AFL  atrial flutter
CABG  coronary artery
bypass graft
ECG  electrocardiogram
PVI  pulmonary vein
isolationwFL, were analyzed. The number of post-operative atrial
rrhythmias in this group would represent the approximate
ncidence expected to occur in a group of patients with
reserved cardiac function undergoing thoracotomy and
ericardiectomy.
urgical techniques. The double-lung transplant tech-
ique for the patient population was a sequential single-lung
mplant procedure using a bilateral anterolateral fourth
nterspace thoracotomy, or a clamshell incision in which the
ternum was divided transversely. After the bronchial anas-
omoses, each donor lung’s pulmonary veins with atrial cuff
ere sutured to an atriotomy in the recipient left atrium.
herefore, 2 separate atriotomies were created (Fig. 1). The
ulmonary artery anastomoses were completed after the
ronchial and pulmonary vein anastomoses. The orthotopic
eart transplant technique for this population consistently
nvolved a bicaval right atrial anastomoses. The recipient
ulmonary veins with atrial cuff were sutured to a single
triotomy in the donor left atrium (Fig. 2).
tatistical methods. Data are presented as absolute values,
ercentages, or mean  SD. Continuous variables were
ompared using a 2-tailed t test. Nominal variables were
ompared using the Fisher exact test (2-tailed). The Bon-
erroni correction was applied when comparing multiple
eans. A value of p  0.05 was considered significant.
esults
he demographics of the groups, along with pre-operative
iagnoses, are listed in Tables 1 and 2. Our major findings
re displayed in Table 3, which lists the incidence and
iming of AF for the transplant and CABG groups. There
Figure 2 Heart Transplant Procedure
Schematic of heart transplantation procedure depicting single donor atriotomy
accepting all 4 recipient pulmonary veins (PVs). The recipient inferior vena cava
(IVC) and superior vena cava (SVC) are attached to the intact donor right
atrium (RA).as a more than 4-fold higher incidence of post-operative
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November 24, 2009:2043–8 Atrial Arrhythmias After Heart or Double-Lung TransplantationF in the lung transplant group and the control group of
ABG patients compared with the heart transplant group
p  0.001). The incidence of post-operative AF in the
ABG group was similar to that of the lung transplant
roup. Of the lung transplant patients with AF, only 2 were
nown to have AF before transplant, and 78% had AF
ithin 1 week after transplant. In contrast, 50% of heart
ransplant patients with AF had AF in the first week after
ransplant. Three arrhythmia episodes occurred later than 1
onth post-operatively in the heart transplant group, the
atest occurring 9 months after transplant. Nine atrial
rrhythmia episodes occurred after 1 month in the lung
ransplant group; the latest was 10 months after transplant.
he average duration of follow-up was 490  316 days
range 9 to 1,170 days) for the lung transplant group and
64  240 days (range 3 to 896 days) for the heart
ransplant group. Five patients in the heart transplant group
2.9%) had AFL, as compared with 9 (7.4%) patients in the
ung transplant group and 5 (3.8%) patients in the CABG
roup. Nine episodes of an atrial arrhythmia could not be
orroborated with an ECG in the lung transplant group, as
ompared with 2 in the heart transplant group.
Table 4 lists selected clinical variables for the atrial
rrhythmia patients, chosen for potential impact on the
ncidence of post-operative AF and as general measures of
everity of clinical course. There was a 4-fold higher rate
f the use of pre-operative beta-blockers in the heart
ransplant patients, but not the use of post-operative beta-
lockers before the onset of an atrial arrhythmia. Three
atients in the lung transplant atrial arrhythmia group were
aking antiarrhythmic agents before transplant (2 amioda-
one, 1 flecainide), and all 3 continued these medications
fter transplant. Five heart transplant atrial arrhythmia
atients were taking amiodarone before transplant, but none
ontinued antiarrhythmic agents after transplant. Both
roups had similar lengths of admission, prolonged use of
emographicsTable 1 Demographics
Lung
(n  122)
Heart
(n  174)
CABG
(n  131)
Age, yrs 46.9  15.7* 51.9  13.3* 63.0  9.4*
Sex, male 48% 82% 76%
p  0.01 coronary artery bypass graft surgery (CABG) versus lung or heart patients.
Pre-Operative DiagnosesTable 2 Pre-Operative Diagnoses
Lung Transplant
Idiopathic pulmonary fibrosis 33%
Cystic fibrosis 26%
Chronic obstructive pulmonary disease 24%
Pulmonary hypertension 6%
Sarcoidosis 6%
Bronchiectasis 4%
Scleroderma 1%
Alpha-1-antitrypsin deficiency 0.7%notropic/pressor agents, complication rates, comorbidities,
nd deaths.
Table 5 lists the immunosuppressive regimens for the
ransplant patients, which were similar in terms of dose and
ype of regimen. Table 6 lists the echocardiographic data for
he transplant patients with AF. These data were from
ost-operative echocardiograms selected within days of the
ccurrence of the atrial arrhythmias. Where quantitative
ata were not available (for right ventricle function and right
trium size), the percent of studies listed as “normal” is
enoted. The lung transplant arrhythmia patients, despite
heir higher incidence of AF, had a more than 3-fold higher
ercentage of normal echocardiographic indexes.
Finally, Table 7 lists the biopsy results of the patients
ith atrial arrhythmias, stratified by International Society
or Heart and Lung Transplantation grade. Overall, only
8% of the lung transplant patients who developed an atrial
rrhythmia had rejection as defined by International Society
or Heart and Lung Transplantation grade 0 or A0,
ompared with 63% of the heart transplant arrhythmia
atients.
iscussion
he incidence of AF is high after thoracic surgery, reaching
50% for procedures involving valve replacement (1,2).
owever, the incidence of AF is well known to be low after
ardiac transplantation (13–16). Given the recent emphasis
n PVI as therapy for AF, one may postulate PVI as being
rotective against AF in the heart transplant recipient.
ecause double-lung transplant procedures also involve
ffective isolation of the pulmonary veins, we sought to
ontrast the incidence of post-operative AF in this popula-
ion against the incidence after heart transplant. The dif-
erences in the incidence of AF between these transplant
roups might point toward alternative explanations for
ost-operative AF other than pulmonary vein sources, since
VI was a common component of both procedures. The
emaining differences between the groups, such as auto-
omic denervation in the transplanted heart, could high-
ight other potential mechanisms for post-operative AF
uch as autonomic modulation.
Our results, which are similar to those reported in
revious lung and heart transplant series (13,14,16–18),
Heart Transplant
Idiopathic dilated cardiomyopathy 48%
Ischemic cardiomyopathy 33%
Hypertrophic cardiomyopathy 6%
Congenital heart disease 4%
Valvular cardiomyopathy 3%
Amyloid cardiomyopathy 3%
Restrictive cardiomyopathy 3%
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Atrial Arrhythmias After Heart or Double-Lung Transplantation November 24, 2009:2043–8eveal a much higher incidence of AF in the post–lung
ransplant group, similar in fact to the incidence in our
ost-CABG patients with preserved left ventricular ejection
raction. There was a preponderance of males in the heart
ransplant group, reflecting the general higher incidence of
eart disease among males, but there is no obvious reason
hy this could explain the difference in AF incidence.
either does the higher incidence in the lung transplant
roup appear to be explained by a higher incidence of
re-operative AF, which was very low.
We also recorded the incidence of AFL, given its asso-
iation with AF and known occurrence after thoracic
urgery. We could not confirm with certainty that the AFL
pisodes were not left atrial in origin, and hence potentially
mpacted by PVI. Nevertheless, including the AFL episodes
n our analysis does not alter our main results.
Both groups had similar average post-transplant lengths
f stay, complication rates, prolonged use of inotropic or
ressor agents, and comorbidities. The heart transplant
roup had a higher use of pre-operative beta-blockers and
miodarone, due probably to the frequent use of these
gents for end-stage heart failure, and the reluctance to use
eta-blockers for advanced pulmonary disease. However,
he use of pre-operative beta-blockers and antiarrhythmic
gents is unlikely to impact arrhythmias in a newly trans-
lanted heart not previously exposed to such agents. The use
f these agents in the post-operative period before the onset
f any atrial arrhythmias was not significantly different
etween the 2 transplant groups.
The higher incidence of AF in the lung transplant group
ccurred despite our observation that the lung transplant
Arrhythmia Incidence and TimingTable 3 Arrhythmia Incidence and Timing
Patients With AF
Heart transplant, n  174 8 (4.6%)*
Lung transplant, n  122 23 (18.9%)*
CABG, n  131 26 (19.8%)*
*p  0.001 heart versus lung transplant or coronary artery bypass gra
AF  atrial fibrillation; N/A  not applicable.
Perioperative Clinical VariablesTable 4 Perioperative Clinical Variables
Average length of stay post-transplant, days
Beta-blocker use
Beta-blocker use after transplant
Antiarrhythmic agents
Antiarrhythmic agents post-transplant
Inotrope/pressor use 5 days post-operatively
Complications†
Comorbidities‡
Deaths (before discharge)*p  0.05. †Most commonly, surgical complications requiring reoperati
commonly, chronic renal failure, diabetes mellitus, and hypertension.rrhythmia patients as a whole did not have larger post-
perative right atrium size. The normalized echocardio-
raphic indexes after lung transplant may reflect the selec-
ion of patients without cor pulmonale and hence reversible
ardiac function and chamber enlargement. However, even
ith normalization of right atrial size, subclinical fibrosis
nd hence altered electrophysiologic properties may persist
n the atria of the lung transplant patients. The lung
ransplant group with atrial arrhythmias also did not tend to
ave pulmonary graft rejection.
Heart transplant patients with atrial arrhythmias in our
eries more commonly had evidence of atrial abnormalities,
ight ventricle dysfunction, or abnormal myocardial biopsy
esults. These results are consistent with prior studies
eporting atrial tachyarrhythmias in heart transplant recip-
ents (13–15,19). Graft rejection resulting in fibrosis or
dema may set up heterogeneities in conduction or repolar-
zation within the atria, leading to AF or AFL. The
umulative data suggest that atrial arrhythmias in post–
eart transplant patients are more often a sequelae of
nderlying myocardial dysfunction, whereas atrial arrhyth-
ias after lung transplant are less related to intrinsic cardiac
auses, similar to patients after CABG with normal left
entricle function. Since, in our study, PVI occurred in both
ransplant groups, pulmonary vein sources for AF do not
ppear to be the primary cause for post-operative AF, nor
oes PVI appear to be the primary protective mechanism
gainst AF for the heart transplant recipients.
Mechanisms proposed for post-operative AF include
nflammation, and various studies have pointed to a bene-
cial effect of anti-inflammatory agents such as steroids
Patients With AF
Pre-Transplant
Patients With AF
Within 1 Week
N/A 4 (50%)
2 (8.7%) 18 (78.3%)
0 22 (84.6%)
ery (CABG).
Lung Transplant
(n  23)
Heart Transplant
(n  8)
32.3 46.8 30.5 21.4
13%* 54%*
19% 15%
10%* 38%*
10% 0
16% 15%
65% 62%
52% 77%
9% 13%on, infections, acute renal failure, and respiratory failure. ‡Most
(
h
e
T
p
r
t
d
e
b
t
b
a
a
p
h
s
l
i
t
r
f
p
t
t
t
g
o
d
d
t
(
o
t
a
t
t
i
t
S
c
a
t
c
s
m
c
w
a
E
w
o
o
a
n
I
b
2047JACC Vol. 54, No. 22, 2009 Dizon et al.
November 24, 2009:2043–8 Atrial Arrhythmias After Heart or Double-Lung Transplantation20–22). It is possible that the low incidence of AF after
eart transplant may be related to the anti-inflammatory
ffect of immunosuppressive agents. However, as noted in
able 5, the immunosuppressive regimen for lung trans-
lant recipients is nearly identical to that for heart transplant
ecipients, arguing against an anti-inflammatory explana-
ion for the difference in AF incidence.
Two possible explanations may be proposed for the
ifference in AF incidence between the 2 groups. One
xplanation is the slightly different surgical technique used
etween the 2 groups. In both the double-lung and heart
ransplant cases, the right atrium is left intact because the
icaval heart transplant technique does not involve a right
triotomy (Fig. 2). However, because the pulmonary veins
re often attached to the extreme lateral ends of the
osterior left atrium, the mass of left atrium excluded by the
eart transplant procedure is larger and includes a larger
ection of the posterior wall than that included during the
ung transplant procedure (Figs. 1 and 2). That might result
n more potentially arrhythmogenic tissue being excluded by
he heart transplant procedure, especially in view of the
ecent focus on the posterior wall of the left atrium as a site
or initiators and drivers of AF (23). Post-lung transplant
atients may also have sources of AF that are distant from
he pulmonary veins, and hence are unaffected by PVI.
Another explanation is cardiac autonomic denervation in
he heart transplant patients. Autonomic factors are known
o be important in arrhythmogenesis, particularly the role of
anglionic plexi in the pathogenesis of AF (24,25). The
mmunosuppressive Regimens, Typical DosesTable 5 Immunosuppressive Regimens, Typical Doses
Post-Heart Transplant
Acute
Methylprednisolone 500 mg IV intraoperative, 125 mg IV every
8 h post-operative, tapering to 30 mg
prednisone by 2 weeks
IL-2 antibody induction
Daclizumab 1 mg/kg IV every 2 weeks for total of
5 doses
Basiliximab
Calcineurin inhibitors
Tacrolimus 1 mg po every 12 h 2 mg
Cyclosporine 100 mg po every 12 h 100 m
Antiproliferative agents
Azathioprine 150 m
Mycophenolate 1 g IV every 12 h 500 m
id  twice a day; IL  interleukin; IV  intravenous; po  by mouth; qd  every day.
Echocardiographic Indexes (AF/AFL Patients)Table 6 Echocardiographic Indexes (AF/AFL
LVEF
RV Function
(% Normal)
AF heart, n  8 54.8 17.7 25*
AF lung, n  23 56.6 11.1 74**p  0.05.
AF  atrial fibrillation; AFL  atrial flutter; LVEF  left ventricular ejectionrthotopic heart transplant procedure results in complete
enervation of the implanted heart, which has been well
ocumented (14,26–28). Late cardiac autonomic reinerva-
ion may occur, but is likely a slow, incomplete process
28,29). In contrast, previous studies using exercise testing
r measures of autonomic nervous system activity support
he preservation of autonomic cardiac innervation in single-
nd double-lung transplant recipients (30–34). It is possible
hat cardiac autonomic denervation may be another impor-
ant mechanism that accounts for the difference in AF
ncidence between heart and lung transplant recipients in
he post-operative setting.
tudy limitations. This study is a retrospective review of
linical and laboratory data, including patients with complex
nd prolonged hospital courses. It is therefore possible that
he observed differences between the transplant groups are a
hance occurrence. Another limitation is the possible omis-
ion of relevant clinical data. However, the electronic
edical records in our hospital system make relatively
omplete access and review of records feasible. Although we
ere unable to locate some ECGs to confirm AF or AFL in
small group of patients, there were more nonlocalized
CGs in the lung transplant group, which if confirmed,
ould sway the results even more toward a higher incidence
f atrial arrhythmias in the lung transplant patients. An-
ther limitation is our assumption that the pulmonary veins
re electrically isolated in the transplant patients, which was
ot confirmed with electrode catheters.
Post-Lung Transplant
nic Acute Chronic
1 g IV intraoperative, 125 mg IV every
8 h post-operative, tapering to
25 mg prednisone by 2 weeks
20 mg IV every 4 days for total of
2 doses
2 mg po every 12 h 2 mg po bid
very 12 h
d 150 mg IV 150 mg po qd
very 12 h 500 mg po every 12 h
ients)
t Atrium Size
(mm)
Right Atrium
(% Normal)
MR Number
Moderate-Severe
4.5 1.5 25* 1
3.7 0.9 91* 1Chro
po bid
g po e
g po q
g po ePat
Leffraction; MR  mitral regurgitation; RV  right ventricle.
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Atrial Arrhythmias After Heart or Double-Lung Transplantation November 24, 2009:2043–8onclusions
n heart transplant recipients, AF is uncommon and occurs
n the setting of myocardial dysfunction and graft rejection.
n contrast, the incidence of AF in double-lung transplant
ecipients is similar to that in post-CABG patients, despite
he absence of graft rejection and cardiac dysfunction.
oreover, PVI alone cannot explain the differences in AF
ncidence between these groups, although the heart trans-
lant procedure may be more antiarrhythmic because of the
arger mass of atria isolated. Cardiac autonomic denervation
ay have a protective effect for heart transplant patients in
he post-operative setting.
eprint requests and correspondence: Dr. José M. Dizon,
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